IMMP Quote, Financials, Valuation and Earnings

Immuron has a net margin of -- compared to Immutep's net margin of --. Immutep's return on equity of -- beat Immuron's return on equity of -53.91%.

Immutep has a consensus price target of $9.50, signalling upside risk potential of 410.75%. On the other hand Immuron has an analysts' consensus of -- which suggests that it could grow by 156.44%. Given that Immutep has higher upside potential than Immuron, analysts believe Immutep is more attractive than Immuron.

Immutep has a beta of 1.803, which suggesting that the stock is 80.329% more volatile than S&P 500. In comparison Immuron has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.931%.

Immutep has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep pays -- of its earnings as a dividend. Immuron pays out -- of its earnings as a dividend.

Immutep quarterly revenues are --, which are smaller than Immuron quarterly revenues of --. Immutep's net income of -- is lower than Immuron's net income of --. Notably, Immutep's price-to-earnings ratio is -- while Immuron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep is -- versus 2.60x for Immuron. Usually stocks with elevated PS ratios are considered overvalued.

Kazia Therapeutics has a net margin of -- compared to Immutep's net margin of --. Immutep's return on equity of -- beat Kazia Therapeutics's return on equity of -1083.16%.

Immutep has a consensus price target of $9.50, signalling upside risk potential of 410.75%. On the other hand Kazia Therapeutics has an analysts' consensus of $2.98 which suggests that it could grow by 360.81%. Given that Immutep has higher upside potential than Kazia Therapeutics, analysts believe Immutep is more attractive than Kazia Therapeutics.

Immutep has a beta of 1.803, which suggesting that the stock is 80.329% more volatile than S&P 500. In comparison Kazia Therapeutics has a beta of 2.495, suggesting its more volatile than the S&P 500 by 149.537%.

Immutep has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep pays -- of its earnings as a dividend. Kazia Therapeutics pays out -- of its earnings as a dividend.

Immutep quarterly revenues are --, which are smaller than Kazia Therapeutics quarterly revenues of --. Immutep's net income of -- is lower than Kazia Therapeutics's net income of --. Notably, Immutep's price-to-earnings ratio is -- while Kazia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep is -- versus 0.01x for Kazia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Mesoblast has a net margin of -- compared to Immutep's net margin of --. Immutep's return on equity of -- beat Mesoblast's return on equity of --.

Immutep has a consensus price target of $9.50, signalling upside risk potential of 410.75%. On the other hand Mesoblast has an analysts' consensus of $27.00 which suggests that it could grow by 136.64%. Given that Immutep has higher upside potential than Mesoblast, analysts believe Immutep is more attractive than Mesoblast.

Immutep has a beta of 1.803, which suggesting that the stock is 80.329% more volatile than S&P 500. In comparison Mesoblast has a beta of 2.500, suggesting its more volatile than the S&P 500 by 150.01%.

Immutep has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mesoblast offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep pays -- of its earnings as a dividend. Mesoblast pays out -- of its earnings as a dividend.

Immutep quarterly revenues are --, which are smaller than Mesoblast quarterly revenues of --. Immutep's net income of -- is lower than Mesoblast's net income of --. Notably, Immutep's price-to-earnings ratio is -- while Mesoblast's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep is -- versus 118.31x for Mesoblast. Usually stocks with elevated PS ratios are considered overvalued.

Opthea has a net margin of -- compared to Immutep's net margin of --. Immutep's return on equity of -- beat Opthea's return on equity of --.

Immutep has a consensus price target of $9.50, signalling upside risk potential of 410.75%. On the other hand Opthea has an analysts' consensus of $1.33 which suggests that it could fall by -60.9%. Given that Immutep has higher upside potential than Opthea, analysts believe Immutep is more attractive than Opthea.

Immutep has a beta of 1.803, which suggesting that the stock is 80.329% more volatile than S&P 500. In comparison Opthea has a beta of 1.011, suggesting its more volatile than the S&P 500 by 1.132%.

Immutep has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Opthea offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Immutep pays -- of its earnings as a dividend. Opthea pays out -- of its earnings as a dividend.

Immutep quarterly revenues are --, which are smaller than Opthea quarterly revenues of --. Immutep's net income of -- is lower than Opthea's net income of --. Notably, Immutep's price-to-earnings ratio is -- while Opthea's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Immutep is -- versus 2,182.10x for Opthea. Usually stocks with elevated PS ratios are considered overvalued.